NCT03083743 2017-03-20
A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection
Shanghai Gebaide Biotechnology Co., Ltd.
Phase 3 Unknown
Clinical Trials
5 trialsNCT00671372 2016-11-02
A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer
Genentech, Inc.
Phase 1 Completed
NCT00873756 2016-11-02
A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
Genentech, Inc.
Phase 1 Completed
NCT00508625 2016-06-14
A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab
Amgen
Phase 2 Completed
NCT00400764 2011-11-23
A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas
Genentech, Inc.
Phase 1/2 Terminated